GeneDx’s Stock Soars—A Tale of Pundits and Praise
GeneDx’s second-quarter results, while undeniably sprightly, were not merely a matter of numbers on a page. Revenue had taken a brisk turn for the better, and the bottom line, once a forlorn figure, had now donned a waistcoat and declared itself in the black. Yet it was the manner in which these figures surpassed the consensus forecasts that truly set the tone for the week. Management, in a moment of uncharacteristic exuberance, had also tweaked its guidance, as though adjusting the sails of a ship in a gale.